Trinitas Regional Medical Center Obligated Group
Consolidated Balance Sheet
At March 31, 2020 and December 31, 2019
(Unaudited)

	March 2020	December 2019
Assets		
Current Assets: Cash and cash equivalents (includes certificates of deposit) Assets whose use is limited Patient accounts receivable, net Other receivables Other current assets Total current assets	\$ 116,732,191 5,251,192 29,556,872 7,175,453 7,862,458 166,578,166	\$ 126,723,117 4,870,024 31,733,480 3,220,611 8,000,940 174,548,172
Assets Whose Use is Limited and Investments		
Assets whose use is limited: Internally designated Other internally designated Donor restricted Investments Total assets whose use is limited and investments	106,470,452 9,807,324 4,615,723 31,673,554 152,567,053	115,276,041 11,098,099 5,200,026 33,638,018 165,212,184
Beneficial Interest in Net Assets of Trinitas Health Foundation	10,021,509	8,096,265
<b>Property and Equipment</b> (net of accumulated depreciation of \$271,560,000 and \$274,383,000 in 2020 and 2019, respectively)	86,119,538	85,804,833
Right-of-Use Assets	11,375,224	11,003,177
Other Assets	6,592,602	6,592,602
Total	\$ 433,254,092	\$ 451,257,233
Liabilities and Net Assets Current Liabilities:	4	
Current portion of long-term debt	\$ 5,580,000 2,195,978	\$ 5,580,000 2,317,590
Current portion of operating lease obligation  Accounts payable, construction payable and accrued expenses	24,044,228	24,739,715
Deferred revenue	7,789,785	7,599,914
Accrued bond interest payable	955,875	1,981,500
Accrued salaries and wages	4,616,072	7,019,729
Estimated settlements with third-party payors	8,136,365	7,865,071
Total current liabilities	53,318,303	57,103,519
Estimated Settlements with Third-party Payors	55,231,168	55,674,298
Long-Term Debt	81,370,219	81,676,371
Operating Lease Obligations	9,179,246	8,685,587
Other Long-Term Liabilities	20,245,999	21,581,564
Total liabilities	219,344,935	224,721,339
Net Assets		
Without donor restrictions	199,271,925	213,239,598
With donor restrictions	14,637,232	13,296,296
Total net assets	213,909,157	226,535,894
Total Page 1	\$ 433,254,092	\$ 451,257,233

Trinitas Regional Medical Center Obligated Group
Consolidated Statement of Operations For the Three Months Ended March 31, 2020 and 2019 (Unaudited)

	March 2020	March 2019
Revenues Net patient service revenue Other revenue	\$ 54,812,947 16,801,955	\$ 57,293,208 16,213,888
Net assets released from restrictions used for operations Total revenues	141,478 71,756,380	197,042 73,704,138
Expenses Salaries and wages	35,461,640	34,570,072
Employee benefits Supplies and other	7,509,130 29,184,312	7,256,979 28,573,712
Depreciation Interest and amortization	2,768,255 651,661	2,822,516 668,663
Total expenses	75,574,998	73,891,942
Operating Loss	(3,818,618)	(187,804)
Nonoperating Gains and (Losses)		
Interest, dividends and other	1,040,448	968,881
Net realized gains and losses on investments	1,369,242	186,224
Change in unrealized gains and (losses) on investments Total nonoperating gains and (losses)	(13,116,591) (10,706,901)	6,351,685 7,506,790
Revenues and Nonoperating Gains	¢ (14 525 510)	¢ 7319006
Over (Under) Expenses	<u>\$ (14,525,519)</u>	\$ 7,318,986

Trinitas Regional Medical Center Obligated Group
Consolidated Statement of Changes in Net Assets
For the Three Months Ended March 31, 2020 and 2019
(Unaudited)

	March 2020	March 2019
Without Donor Restrictions:		
Revenues and nonoperating gains over (under) expenses Net assets released from restrictions	\$ (14,525,519)	\$ 7,318,986
used for purchase of property and equipment	557,841	1,012,471
Increase (decrease) in without donor restrictions net assets	(13,967,678)	8,331,457
With Donor Restrictions:		
Contributions	136,237	1,457,747
Grants	-	870,000
Interest and dividends	3,667	3,133
Change in unrealized gains and (losses) on investments	(24,888)	41,120
Net assets released from restrictions Change in beneficial interest in net assets of	(699,319)	(1,209,513)
Trinitas Health Foundation	1,925,244	(918,033)
Increase (decrease) in with donor restrictions net assets	1,340,941_	244,454
Increase (Decrease) in Net Assets	(12,626,737)	8,575,911
Net Assets		
Beginning of year	226,535,894	201,886,710
End of year	\$ 213,909,157	\$ 210,462,621

Trinitas Regional Medical Center Obligated Group
Consolidated Statement of Cash Flows
For the Three Months Ended March 31, 2020 and 2019
(Unaudited)

Cash Flows from Operating Activities   Increases (generases) in real sasets   Sase		March 2020	March 2019
Adjustments to reconcile increase in net assets to net cash provided by operating activities:  Depreciation  Lease expense  Expense expense  Amortization of deferred financing costs  Amortization of deferred bond premium  Restricted contributions for capital additions  Change in net unrealized gains and losses on other than trading securities  It rading securities  Net realized gains and losses on investments  Net and the contributions of the first part of the provided of the provided provided gains and losses on investments  Net cash used assets and other assets of the gain part of the provided by investments and accrued expenses  Net cash used in operating activities  Accrued band interest payable and accrued expenses  Net cash used in operating activities  Accrued salaries and wages  Accrued salaries and wages  Net cash used in operating activities  Acquisition of property and equipment and construction  Net cash used in operating activities  Acquisition of property and equipment and construction  Acquisition of property and equipment and construction  Net cash used in investing activities  Acquisition of property and equipment and construction  Net cash used in investing activities  Acquisition of property and equipment and construction  Net cash used in investing activities  Acquisition of property and equipment and construction  Net cash provided by financing activities  Ac		+ //	
Common   C		\$ (12,626,737)	\$ 8,575,911
Depreciation         2,768,255         2,822,516           Lease expense         938,074         904,977           Change in right-of-use asset and lease obligation, net         75           Amordization of deferred financing costs         17,988         19,206           Amordization of deferred bond premium         (324,140)         (374,950)           Restricted contributions for capital additions         (57,841)         (1,012,471)           Change in net unrealized gains and losses on other than trading securities         13,116,591         (6,351,885)           Nat realized gains and losses on investments         (1,399,242)         918,033           Change in beneficial interest in net assets of Trinitas Health Foundation         (1,925,244)         918,033           Change in assets and liabilities:         2,280,770         (13,861)           Patient accounts receivable         2,280,770         (13,861)           Other cruerity assets and other assets         (40,43,880)         302,913           Other receivables         (40,43,880)         302,913           Other current assets and other assets         (212,461)         (1,186,769)           Accounts payable, construction payable and accrued expenses         (212,461)         (1,186,769)           Deferred revenue         (2,00,667)         (2,276,860)			
Chase expense		0.700.055	0.000 546
Change in right-of-use asset and lease obligation, net         75         47           Amortization of deferred financing costs         17,988         19,206           Amortization of deferred bond premium         (324,140)         (374,950)           Restricted contributions for capital additions         (557,841)         (1,012,471)           Change in net unrealized gains and losses on other than trading securities         (1,369,242)         (186,224)           Net realized gains and losses on investments         (1,369,242)         (186,224)           Change in beneficial interest in net assets of Trinitas Health Foundation         (1,925,244)         918,033           Change in sasets and inseases of Early and the sasets and seasets and other assets         (359,669)         (17,75,688)           Change in assets and inseases         (359,669)         (17,75,688)           Accounts payable, construction payable and accrued expenses         (212,461)         (1,186,759)           Other current assets and other assets         (359,669)         (17,75,688)           Accounts payable, construction payable and accrued expenses         (212,461)         (1,186,759)           Other current assets and wages         (2,26,850)         (2,762,865)           Accrued Salaries and wages         (2,743,861)         (2,743,861)           Estimated settlements with third-party payors			
Amoritzation of deferred financing costs         17,988         19,206           Amoritzation of deferred bond premium         (324,140)         (374,950)           Restricted contributions for capital additions         (557,841)         (1,012,471)           Change in net unrealized gains and losses on other than trading securities         13,116,591         (6,351,685)           Net realized gains and losses on investments         (1,369,242)         (186,224)           Change in beneficial interest in net assets of Trinitas Health Foundation         (1,925,244)         918,033           Change in assets and ilabilities:         2,280,770         (13,861)           Other courser testivable         (4,043,880)         302,913           Other current assets and other assets         (359,669)         (1,775,658)           Accounts payable, construction payable and accrued expenses         (212,461)         (1,86,759)           Deferred revenue         (89,871)         (2,256,850)           Accrued bond interest payable         (1,025,625)         (1,090,607)           Accrued bond interest payable, and wages         (2,403,657)         (2,763,861)           Selimated settlements with third-party payors         (1,135,651)         990,960           Chher long-term liabilities         (31,335,655)         990,960           Lease payments			904,977
Amortization of deferred bond premium         (324,140)         (374,950)           Restricted contributions for capital additions         (557,841)         (1012,471)           Change in net unrealized gains and losses on other than trading securities         (1,389,242)         (186,224)           Net realized gains and losses on investments         (1,389,242)         (186,224)           Change in beneficial interest in net assets of Trinitas Health Foundation         (1,925,244)         918,033           Change in assets and liabilities:         2,280,770         (13,861)           Patient accounts receivable         2,280,770         (13,861)           Other current assets and other assets         359,669)         (1,775,688)           Accounts payable, construction payable and accrued expenses         189,871         (2,266,850)           Deferred revenue         189,871         (2,256,850)           Accrued Salaries and wages         (2,403,867)         (2,703,861)           Estimated settlements with third-party payors         (171,836)         (1,295,940)           Other long-term liabilities         (338,149)         (904,977)           Net cash used in operating activities         (3,082,959)         (99,5085)           Lease payments         (3,082,959)         (995,685)           Net cash used in investing activities			10.206
Restricted contributions for capital additions			·
Change in net unrealized gains and losses on other than trading securities   13,116,591 (6,351,685)   166,224  (186,224)   186,224  (186,224)   186,224  (186,224)   186,224  (186,224)   186,224  (186,224)   186,224  (186,224)   186,224  (186,224)   186,224  (186,224)   186,233  (186,233)   186,233  (			
13,116,591 (6,351,685)   Net realized gains and losses on investments (1,369,242) (186,224)   Change in beneficial interest in net assets of Trinitas Health Foundation (1,925,244)   918,033   Trinitas Health Foundation (1,925,244)   918,033   Change in assets and liabilities:   Patient accounts receivable (2,280,770 (13,861)   302,913 (1775,658)   Cher receivables (40,43,880) (302,913 (30,969) (1,775,658)   Cher current assets and other assets (359,669) (1,775,658)   Accounts payable, construction payable and accrued expenses (212,461) (1,186,759)   Cherred revenue (1,025,625) (1,090,407)   Accrued bond interest payable (1,025,625) (1,090,407)   Accrued salaries and wages (2,403,657) (2,763,861)   Estimated settlements with third-party payors (171,836) (1,335,565) (2,763,861)   Estimated settlements with third-party payors (171,836) (1,335,565) (1,990,960)   Cher long-term liabilities (1,335,565) (90,990,960)   (90,977)   Net cash used in operating activities (1,336,565) (1,982,422) (2,123,247)   Cash Flows from Investing Activities (1,334,703) (1,882,599)   (995,685)   Net cash used in investing activities (2,748,256) (2,748,256) (2,878,284)   Cash Flows from Financing Activities (2,748,256) (2,878,284)   Cash And Cash Equivalents, Ending (3,98,906)   (1,72,837) (3,989,060)   (1,72,837) (3,989,0		(557,641)	(1,012,471)
Net realized gains and losses on investments		12 116 501	(G 351 695)
Change in beneficial interest in net assets of Trinitas Health Foundation (1,925,244) 918,033   Change in assets and labilities: Patient accounts receivable (4,043,880) 302,913   Other current assets and other assets (359,669) (1,775,658)   Accounts payable, construction payable and accrued expenses (212,461) (1,186,759)   Deferred revenue (189,871) (2,256,850) (2,256,850)   Accounts payable, construction payable and accrued expenses (214,0461) (1,186,759)   Deferred revenue (189,871) (2,256,850) (1,090,407)   Accrued band interest payable (1,025,625) (1,090,407)   Accrued salaries and wages (2,403,657) (2,763,861)   Estimated settlements with third-party payors (171,836) (1,259,940)   Other long-term liabilities (1,335,555) (990,960)   Other long-term liabilities (1,335,555) (1,090,4077)   Other long-term liabilities (1,335,555) (1,090,4077)   Other long-term liabilities (1,335,555) (1,090,4077)   Other long-term liabilities (1,335,555) (1,393,404) (1,345,555) (1,393,404) (1,345,555)   Other long-term liabilities (1,335,555) (1,393,404) (1,345,555) (1,393,404) (1,345,555) (1,393,404) (1,345,555) (1,393,404) (1,345,555) (1,393,404) (1,345,555) (1			
Trinitas Health Foundation		(1,309,242)	(100,224)
Change in assets and liabilities:   Patient accounts receivable   2,280,770   (13,861)   Cher receivables   (4,043,880)   302,913   Cher current assets and other assets   (359,669)   (1,776,658)   Accounts payable, construction payable and accrued expenses   (212,461)   (1,186,759)   Captured revenue   189,871   (2,256,850)   Accrued bond interest payable   (1,025,625)   (1,090,407)   Accrued salaries and wages   (2,403,657)   (2,763,861)   Estimated settlements with third-party payors   (171,836)   1,259,940   Cher long-term liabilities   (1335,655)   990,960   Clease payments   (938,149)   (904,977)   Net cash used in operating activities   (7,982,422)   (2,123,247)   Cash Flows from Investing Activities   (3,082,959)   (995,685)   Acquisition of property and equipment and construction   (3,082,959)   (995,685)   Acquisition of property and equipment and construction   (3,082,959)   (995,685)   Acquisition of property and equipment and construction   (3,082,959)   (995,685)   Acquisition of property and equipment and construction   (3,082,959)   (995,685)   Acquisition of property and equipment and construction   (3,082,959)   (995,685)   Acquisition of property and equipment and construction   (3,082,959)   (995,685)   Acquisition of property and equipment and construction   (3,082,959)   (3,		(4.005.044)	018 033
Patient accounts receivable		(1,925,244)	910,033
Other receivables         (4,043,880)         302,913           Other current assets and other assets         (399,669)         (1,775,658)           Accounts payable, construction payable and accrued expenses         (212,461)         (1,186,759)           Deferred revenue         189,871         (2,256,850)           Accrued bond interest payable         (1,025,625)         (1,090,407)           Accrued salaries and wages         (2,403,657)         (2,763,657)           Estimated settlements with third-party payors         (171,836)         1,259,940           Other long-term liabilities         (1335,655)         990,960           Lease payments         (938,149)         (904,977)           Net cash used in operating activities         (7,982,422)         (2,123,247)           Cash Flows from Investing Activities         (30,82,959)         (995,685)           Acquisition of property and equipment and construction         (3,082,959)         (995,685)           Purchases of investments and assets whose use is limited, net         334,703         (1,882,599)           Net cash used in investing activities         557,841         1,012,471           Net cash Flows from Financing Activities         557,841         1,012,471           Net cash provided by financing activities         557,841         1,012,471	•	2 220 770	(12 861)
Other current assets and other assets         (359,669)         (1,775,658)           Accounts payable, construction payable and accrued expenses         (212,461)         (1,186,759)           Deferred revenue         189,871         (2,256,850)           Accrued bond interest payable         (1,025,625)         (1,090,407)           Accrued salaries and wages         (2,403,657)         (2,763,861)           Estimated settlements with third-party payors         (1,335,565)         990,960           Other long-term liabilities         (1,335,565)         990,960           Lease payments         (938,149)         (904,977)           Net cash used in operating activities         (3,082,959)         (995,685)           Acquisition of property and equipment and construction         (3,082,959)         (995,685)           Purchases of investments and assets whose use is limited, net         334,703         (1,882,599)           Net cash used in investing activities         (2,748,256)         (2,878,284)           Cash Flows from Financing Activities         557,841         1,012,471           Net cash provided by financing activities         557,841         1,012,471           Net cash provided by financing activities         (10,172,837)         (3,989,060)           Cash and Cash Equivalents, Beginning         135,274,979			
Accounts payable, construction payable and accrued expenses         (212,461)         (1,186,759)           Deferred revenue         189,871         (2,256,850)           Accrued bond interest payable         (1,025,625)         (1,090,407)           Accrued salaries and wages         (2,403,657)         (2,763,861)           Estimated settlements with third-party payors         (171,836)         1,259,940           Other long-term liabilities         (1,335,555)         990,960           Lease payments         (938,149)         (904,977)           Net cash used in operating activities         (7,982,422)         (2,123,247)           Cash Flows from Investing Activities         (3,082,959)         (995,685)           Acquisition of property and equipment and construction         (3,082,959)         (995,685)           Purchases of investments and assets whose use is limited, net         334,703         (1,882,599)           Net cash used in investing activities         557,841         1,012,471           Cash Flows from Financing Activities         557,841         1,012,471           Net cash provided by financing activities         557,841         1,012,471           Net Decrease in Cash and Cash Equivalents         (10,172,837)         (3,989,060)           Cash and Cash Equivalents, Ending         \$125,102,142         \$	= ***=* : = = = : : :::: : : :		
Deferred revenue			
Accrued bond interest payable         (1,025,625)         (1,090,407)           Accrued salaries and wages         (2,403,657)         (2,763,861)           Estimated settlements with third-party payors         (171,836)         1,259,940           Other long-term liabilities         (1,335,565)         990,960           Lease payments         (938,149)         (904,977)           Net cash used in operating activities         (7,982,422)         (2,123,247)           Cash Flows from Investing Activities         (3,082,959)         (995,685)           Acquisition of property and equipment and construction         (3,082,959)         (995,685)           Net cash used in investing activities         (2,748,256)         (2,878,284)           Net cash used in investing activities         (2,748,256)         (2,878,284)           Cash Flows from Financing Activities         557,841         1,012,471           Net cash provided by financing activities         557,841         1,012,471           Net Decrease in Cash and Cash Equivalents         (10,172,837)         (3,989,060)           Cash and Cash Equivalents, Beginning         135,274,979         137,141,823           Cash and Cash Equivalents, Ending         \$125,102,142         \$133,152,763           Supplemental Disclosure of Cash Flow Information, Interest paid         \$1,983,438 <td>• •</td> <td></td> <td></td>	• •		
Accrued salaries and wages         (2,403,657)         (2,763,861)           Estimated settlements with third-party payors         (171,836)         1,259,940           Other long-term liabilities         (1938,165)         990,960           Lease payments         (938,149)         (904,977)           Net cash used in operating activities         (7,982,422)         (2,123,247)           Cash Flows from Investing Activities         (3,082,959)         (995,685)           Acquisition of property and equipment and construction         (3,082,959)         (995,685)           Purchases of investments and assets whose use is limited, net         334,703         (1,882,599)           Net cash used in investing activities         (2,748,256)         (2,878,284)           Cash Flows from Financing Activities         557,841         1,012,471           Net cash provided by financing activities         557,841         1,012,471           Net cash provided by financing activities         (10,172,837)         (3,989,060)           Cash and Cash Equivalents, Beginning         135,274,979         137,141,823           Cash and Cash Equivalents, Ending         \$1,983,438         \$2,114,813           Reconciliation of Cash and Cash Equivalents and Restricted         \$1,983,438         \$2,114,813           Reconciliation of Cash and Cash Equivalents and Rest			
Estimated settlements with third-party payors			
Other long-term liabilities         (1,335,565)         990,960           Lease payments         (938,149)         (904,977)           Net cash used in operating activities         (7,982,422)         (2,123,247)           Cash Flows from Investing Activities         (3,082,959)         (995,685)           Acquisition of property and equipment and construction         (3,082,959)         (1,882,599)           Net cash used in investing activities         (2,748,256)         (2,878,284)           Cash Flows from Financing Activities         557,841         1,012,471           Net cash provided by financing activities         557,841         1,012,471           Net cash provided by financing activities         (10,172,837)         (3,989,060)           Cash and Cash Equivalents, Beginning         135,274,979         137,141,823           Cash and Cash Equivalents, Ending         \$125,102,142         \$133,152,763           Supplemental Disclosure of Cash Flow Information, Interest paid         \$1,983,438         \$2,114,813           Reconciliation of Cash and Cash Equivalents and Restricted Cash and Cash Equivalents:         \$116,732,191         \$125,414,919           Current portion of assets whose use is limited, under trust indenture Assets whose use is limited, included in donor restricted         3,118,759         2,667,038			
Lease payments         (938,149)         (904,977)           Net cash used in operating activities         (7,982,422)         (2,123,247)           Cash Flows from Investing Activities         (3,082,959)         (995,685)           Acquisition of property and equipment and construction         (3,082,959)         (995,685)           Purchases of investments and assets whose use is limited, net         334,703         (1,882,599)           Net cash used in investing activities         (2,748,256)         (2,878,284)           Cash Flows from Financing Activities         557,841         1,012,471           Net cash provided by financing activities         557,841         1,012,471           Net Decrease in Cash and Cash Equivalents         (10,172,837)         (3,989,060)           Cash and Cash Equivalents, Beginning         135,274,979         137,141,823           Cash and Cash Equivalents, Ending         \$125,102,142         \$133,152,763           Supplemental Disclosure of Cash Flow Information, Interest paid         \$1,983,438         2,114,813           Reconciliation of Cash and Cash Equivalents and Restricted           Cash and cash equivalents         \$116,732,191         \$125,414,919           Current portion of assets whose use is limited, under trust indenture         5,251,192         5,070,806           Assets whose use	· · · · · · · · · · · · · · · · · · ·		
Net cash used in operating activities  Cash Flows from Investing Activities Acquisition of property and equipment and construction Purchases of investments and assets whose use is limited, net 334,703 (1,882,599) Net cash used in investing activities  Cash Flows from Financing Activities Restricted contributions for capital additions Net cash provided by financing activities  Restricted contributions for capital additions Net cash provided by financing activities  (10,172,837)  Ret Decrease in Cash and Cash Equivalents  (10,172,837)  Cash and Cash Equivalents, Beginning  135,274,979  137,141,823  Cash and Cash Equivalents, Ending  Supplemental Disclosure of Cash Flow Information, Interest paid  Reconciliation of Cash and Cash Equivalents and Restricted Cash and Cash Equivalents:  Cash and Cash Equivalents  Cash and Cash Equivalents  Carrent portion of assets whose use is limited, under trust indenture Assets whose use is limited, included in donor restricted  3,118,759  2,667,038	_		
Cash Flows from Investing Activities Acquisition of property and equipment and construction Purchases of investments and assets whose use is limited, net 334,703 (1,882,599) Net cash used in investing activities (2,748,256)  Cash Flows from Financing Activities Restricted contributions for capital additions Net cash provided by financing activities  Net Decrease in Cash and Cash Equivalents  Cash and Cash Equivalents, Beginning  Cash and Cash Equivalents, Ending  Supplemental Disclosure of Cash Flow Information, Interest paid  Reconciliation of Cash and Cash Equivalents and Restricted Cash and Cash Equivalents  Cash and Cash Equivalen			
Acquisition of property and equipment and construction Purchases of investments and assets whose use is limited, net 334,703 (1,882,599) Net cash used in investing activities (2,748,256) (2,878,284)  Cash Flows from Financing Activities Restricted contributions for capital additions Net cash provided by financing activities 557,841 1,012,471 Net Decrease in Cash and Cash Equivalents (10,172,837) (3,989,060)  Cash and Cash Equivalents, Beginning 135,274,979 137,141,823  Cash and Cash Equivalents, Ending \$125,102,142 \$133,152,763  Supplemental Disclosure of Cash Flow Information, Interest paid  Reconciliation of Cash and Cash Equivalents and Restricted Cash and Cash Equivalents Current portion of assets whose use is limited, under trust indenture Assets whose use is limited, included in donor restricted 3,118,759 2,667,038	Net cash used in operating activities	(1,902,422)	(2,123,247)
Purchases of investments and assets whose use is limited, net Net cash used in investing activities (2,748,256) (2,878,284)  Cash Flows from Financing Activities Restricted contributions for capital additions Net cash provided by financing activities  Restricted contributions for capital additions Net cash provided by financing activities  Net Decrease in Cash and Cash Equivalents  Cash and Cash Equivalents, Beginning  Cash and Cash Equivalents, Beginning  Cash and Cash Equivalents, Ending  Supplemental Disclosure of Cash Flow Information, Interest paid  Reconciliation of Cash and Cash Equivalents and Restricted Cash and Cash Equivalents: Cash and Cash equivalents  Cash and cash equivalents  Current portion of assets whose use is limited, under trust indenture Assets whose use is limited, included in donor restricted  3,118,759  (1,882,599) (2,748,256) (2,878,284) (2,878,284)  1,012,471  1	Cash Flows from Investing Activities		
Net cash used in investing activities(2,748,256)(2,878,284)Cash Flows from Financing Activities557,8411,012,471Net cash provided by financing activities557,8411,012,471Net Decrease in Cash and Cash Equivalents(10,172,837)(3,989,060)Cash and Cash Equivalents, Beginning135,274,979137,141,823Cash and Cash Equivalents, Ending\$125,102,142\$133,152,763Supplemental Disclosure of Cash Flow Information, Interest paid\$1,983,438\$2,114,813Reconciliation of Cash and Cash Equivalents and Restricted Cash and Cash Equivalents: Cash and cash equivalents\$116,732,191\$125,414,919Current portion of assets whose use is limited, under trust indenture Assets whose use is limited, included in donor restricted\$1,18,7595,070,806	Acquisition of property and equipment and construction	(3,082,959)	
Cash Flows from Financing Activities557,8411,012,471Net cash provided by financing activities557,8411,012,471Net Decrease in Cash and Cash Equivalents(10,172,837)(3,989,060)Cash and Cash Equivalents, Beginning135,274,979137,141,823Cash and Cash Equivalents, Ending\$125,102,142\$133,152,763Supplemental Disclosure of Cash Flow Information, Interest paid\$1,983,438\$2,114,813Reconciliation of Cash and Cash Equivalents and Restricted Cash and Cash Equivalents: Cash and cash equivalents: Current portion of assets whose use is limited, under trust indenture Assets whose use is limited, included in donor restricted\$116,732,191 5,070,806 3,118,759\$125,414,919 5,070,806 2,667,038	Purchases of investments and assets whose use is limited, net		
Restricted contributions for capital additions Net cash provided by financing activities  Net Decrease in Cash and Cash Equivalents  Cash and Cash Equivalents, Beginning  Cash and Cash Equivalents, Ending  Supplemental Disclosure of Cash Flow Information, Interest paid  Reconciliation of Cash and Cash Equivalents and Restricted  Cash and Cash Equivalents:  Cash and Cash equivalents  Current portion of assets whose use is limited, under trust indenture  Assets whose use is limited, included in donor restricted  3,118,759  2,667,038	Net cash used in investing activities	(2,748,256)	(2,878,284)
Restricted contributions for capital additions Net cash provided by financing activities  Net Decrease in Cash and Cash Equivalents  Cash and Cash Equivalents, Beginning  Cash and Cash Equivalents, Ending  Supplemental Disclosure of Cash Flow Information, Interest paid  Reconciliation of Cash and Cash Equivalents and Restricted  Cash and Cash Equivalents:  Cash and Cash equivalents  Current portion of assets whose use is limited, under trust indenture  Assets whose use is limited, included in donor restricted  3,118,759  2,667,038	Cook Flows from Financing Activities		
Net cash provided by financing activities 557,841 1,012,471  Net Decrease in Cash and Cash Equivalents (10,172,837) (3,989,060)  Cash and Cash Equivalents, Beginning 135,274,979 137,141,823  Cash and Cash Equivalents, Ending \$125,102,142 \$133,152,763  Supplemental Disclosure of Cash Flow Information, Interest paid \$1,983,438 \$2,114,813  Reconciliation of Cash and Cash Equivalents and Restricted Cash and Cash Equivalents:  Cash and Cash equivalents \$116,732,191 \$125,414,919  Current portion of assets whose use is limited, under trust indenture 5,251,192 5,070,806  Assets whose use is limited, included in donor restricted 3,118,759 2,667,038		557 841	1 012 471
Net Decrease in Cash and Cash Equivalents (10,172,837) (3,989,060)  Cash and Cash Equivalents, Beginning 135,274,979 137,141,823  Cash and Cash Equivalents, Ending \$125,102,142 \$133,152,763  Supplemental Disclosure of Cash Flow Information, Interest paid \$1,983,438 \$2,114,813  Reconciliation of Cash and Cash Equivalents and Restricted Cash and Cash Equivalents:  Cash and Cash Equivalents \$116,732,191 \$125,414,919  Current portion of assets whose use is limited, under trust indenture 5,251,192 5,070,806  Assets whose use is limited, included in donor restricted 3,118,759 2,667,038			
Cash and Cash Equivalents, Beginning  Cash and Cash Equivalents, Ending  Supplemental Disclosure of Cash Flow Information, Interest paid  Reconciliation of Cash and Cash Equivalents and Restricted Cash and Cash Equivalents: Cash and cash equivalents Current portion of assets whose use is limited, under trust indenture Assets whose use is limited, included in donor restricted  135,274,979  \$ 137,141,823  \$ 133,152,763  \$ 1,983,438  \$ 2,114,813  \$ 125,414,813  \$ 125,414,919  5,070,806  3,118,759  2,667,038	Net cash provided by financing activities	307,041	1,012,477
Cash and Cash Equivalents, Ending  Supplemental Disclosure of Cash Flow Information, Interest paid  Reconciliation of Cash and Cash Equivalents and Restricted Cash and Cash Equivalents: Cash and cash equivalents Current portion of assets whose use is limited, under trust indenture Assets whose use is limited, included in donor restricted  \$ 125,102,142 \$ 133,152,763  \$ 1,983,438 \$ 2,114,813  \$ 116,732,191 \$ 125,414,919  5,070,806  3,118,759 5,070,806	Net Decrease in Cash and Cash Equivalents	(10,172,837)	(3,989,060)
Supplemental Disclosure of Cash Flow Information, Interest paid  Reconciliation of Cash and Cash Equivalents and Restricted Cash and Cash Equivalents: Cash and cash equivalents Current portion of assets whose use is limited, under trust indenture Assets whose use is limited, included in donor restricted  \$ 1,983,438 \$ 2,114,813  \$ 116,732,191 \$ 125,414,919  5,070,806  3,118,759 5,070,806	Cash and Cash Equivalents, Beginning	135,274,979	137,141,823
Reconciliation of Cash and Cash Equivalents and Restricted  Cash and Cash Equivalents: Cash and cash equivalents Current portion of assets whose use is limited, under trust indenture Assets whose use is limited, included in donor restricted  \$ 1,983,438 \$ 2,114,813  \$ 125,414,919  5,070,806  3,118,759 \$ 5,070,806	Cash and Cash Equivalents, Ending	\$ 125,102,142	\$ 133,152,763
Reconciliation of Cash and Cash Equivalents and Restricted  Cash and Cash Equivalents: Cash and cash equivalents Current portion of assets whose use is limited, under trust indenture Assets whose use is limited, included in donor restricted  \$ 1,983,438 \$ 2,114,813  \$ 125,414,919  5,070,806  3,118,759 \$ 5,070,806	Supplemental Displacure of Cash Flow Information		
Cash and Cash Equivalents:\$116,732,191\$125,414,919Cash and cash equivalents\$1,732,191\$125,414,919Current portion of assets whose use is limited, under trust indenture5,251,1925,070,806Assets whose use is limited, included in donor restricted3,118,7592,667,038		\$ 1,983,438	\$ 2,114,813
Cash and cash equivalents \$116,732,191 \$125,414,919 Current portion of assets whose use is limited, under trust indenture 5,251,192 5,070,806 Assets whose use is limited, included in donor restricted 3,118,759 2,667,038			
Current portion of assets whose use is limited, under trust indenture 5,251,192 5,070,806 Assets whose use is limited, included in donor restricted 3,118,759 2,667,038			A 108 111 616
Assets whose use is limited, included in donor restricted 3,118,759 2,667,038			
	Current portion of assets whose use is limited, under trust indenture		
Total cash, cash equivalents and restricted cash and cash equivalents \$125,102,142 \$133,152,763	Assets whose use is limited, included in donor restricted	3,118,759	2,667,038
	Total cash, cash equivalents and restricted cash and cash equivalents	\$ 125,102,142	\$ 133,152,763

Notes to Consolidated Financial Statements
March 31, 2020
(Unaudited)

## 1. Reporting Organizations

The consolidated financial statements include the accounts of Trinitas Regional Medical Center (the "Medical Center"), Marillac Corporation ("Marillac"), a wholly owned subsidiary of the Medical Center and Trinitas Physicians Practice, LLC.

Elizabeth General Medical Center and St. Elizabeth Hospital in 2000, merged to form Trinitas Hospital, a not-for-profit, tax-exempt, voluntary, acute health care provider located in Elizabeth, New Jersey. Trinitas Hospital officially changed its name to Trinitas Regional Medical Center as of October 2008. The Medical Center provides inpatient, outpatient, and emergency care services for local residents. Admitting physicians are primarily practitioners from the local area.

Marillac, a not-for-profit, tax-exempt corporation pursuant to Section 501(c)(3) of the Internal Revenue Code, owns and operates a medical office building in Elizabeth, New Jersey.

Trinitas Physicians Practice, LLC, (TPP, LLC) a New Jersey professional limited liability company (LLC), a for-profit taxable entity.

The sole member of the Medical Center is Trinitas Health (the "Parent"), a tax-exempt holding company. Both the Parent and the Medical Center are tax-exempt organizations, pursuant to Section 501(c)(3) of the Internal Revenue Code.

The Medical Center is an affiliated member of the Parent, the controlling entity. Other affiliates of Trinitas Health include: Trinitas Healthcare Corporation, Trinitas Health Services Corporation and subsidiary, and Trinitas Health Foundation and Affiliate (the "Foundation"). Only the Medical Center's financial statements and its subsidiaries including Marillac and Trinitas Physicians Practice, LLC are presented herein. The Parent's affiliates, with the exception of Trinitas Health Services Corporation, are not-for-profit, tax-exempt organizations. Trinitas Health Services Corporation is a for-profit, taxable entity.

#### 2. Presentation

The consolidated financial statements are unaudited and include all adjustments which are, in the opinion of Management, necessary for a fair presentation of the Obligated Group's financial position at March 31, 2020 and December 31, 2019, its result of operations and its changes in net assets and cash flows for the three months ended March 31, 2020 and 2019 in conformity with accounting principles generally accepted in the United States of America. Certain information and footnote disclosures normally included in financial statements prepared in accordance with such accounting principles have been omitted.

These consolidated financial statements should be read in conjunction with Trinitas Regional Medical Center's audited consolidated financial statements and notes thereto for the years ended December 31, 2019.

#### 3. Net Patient Service Revenue

Patient care service revenues are recognized at the amount that reflects the consideration to which the Medical Center expects to be entitled to in exchange for providing patient care. These amounts are due from patients, third-party payors (including commercial and governmental programs), and others and includes variable consideration for retroactive revenue adjustments due to settlement of audits, reviews and investigations. Generally, the Medical Center bills the patients and third-party payors several days after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied.

Notes to Consolidated Financial Statements
March 31, 2020
(Unaudited)

Performance obligations are determined based on the nature of the services provided by the Medical Center. Revenue for performance obligations satisfied over time is recognized based on actual services incurred in relation to total expected (or actual) payments. The Medical Center believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients in the Medical Center receiving inpatient acute care services. The Medical Center measures the performance obligation from admission into the facility to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge. Revenue for performance obligations satisfied at a point in time are recognized when services are provided and the Medical Center does not believe it is required to provide additional services to the patient.

Generally, because all the Medical Center's performance obligations relate to contracts with a duration of less than one year, the Medical Center has elected to apply the optional exemption provided in Accounting Standard Codification ("ASC") 606-10-50-14(a) and, therefore, the Medical Center is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

The Medical Center determines the transaction price based on standard charges for services provided, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with the Medical Center's policy, and /or implicit price concessions provided to uninsured patients. The Medical Center determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies and historical experience. The Medical Center determines its estimate of implicit price concessions based on its historical collection experience with this class of patients.

The composition of the Medical Center's patient care service revenue by payor (which excludes state subsidies) for the three months ended March 31, 2020 and 2019 is as follows:

 2020		2019
\$ 20,768,285	\$	216,355,99
19,051,157		21,768,262
14,454,290		13,294,530
 539,215		594,817
\$ 54,812,947	\$	57,293,208
\$	\$ 20,768,285 19,051,157 14,454,290 539,215	\$ 20,768,285 \$ 19,051,157 14,454,290 539,215

The composition of patient care service revenue based on the Medical Center's lines of business (which excludes state subsidies) for the three months ended March 31, 2020 and 2019 is as follows:

	2020		2019
Medical Center	\$ 51,437,552		5 54,312,642
Long-term care	1,838,465		1,684,674
Physicians practice	1,536,930	- —	1,295,892
Total	\$ 54,812,947	{	57,593,208

Notes to Consolidated Financial Statements March 31, 2020 (Unaudited)

Agreements with third-party payors typically provide for payments at amounts less than established charges. A summary of the payment arrangements with major third-party payors are as follows:

- Medicare: Certain inpatient acute care services are paid at prospectively determined rates per discharge based on clinical, diagnostic and other factors. Certain services are paid based on cost-reimbursement methodologies subject to certain limits. Physician services are paid based upon established fee schedules. Outpatient services are paid using prospectively determined rates. Reimbursements for cost reimbursable items are received at tentative interim rates, with final settlement determined after submission of annual cost reports by the Medical Center and audits thereof by the Medicare fiscal intermediary. The Medical Center's Medicare cost reports have been settled by the Medicare fiscal intermediary through December 31, 2015.
- Medicaid: Reimbursements for Medicaid services are generally paid at prospectively determined rates per discharge, per occasion of service or per covered member. Outpatient services are paid based on a cost reimbursement methodology. The Medicaid Center's Medicaid cost reports have been settled by the Medicaid fiscal intermediary through December 31, 2016.
- Other: Payment agreements with certain commercial managed care, Medicare and Medicaid managed care insurance carriers, health maintenance organizations and preferred provider organizations provide for payment using prospectively determined rates per discharge, or per diem, or discounts from established charges and prospectively determined daily rates.

Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Medical Center's compliance with these laws and regulations, and it is not possible to determine the impact (if any) such claims or penalties would have upon the Medical Center. In addition, the contracts the Medical Center has with commercial payors also provide for retroactive audit and review of claims.

Settlements with third-party payors for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Medical Center's historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews and investigations. Revenue received under third-party arrangements is subject to audit and retroactive adjustments. For the three months ended March 31, 2020 and 2019, respectively, \$636,423 and \$-0- was recorded as a positive transaction price adjustment in net patient service revenue in the consolidated statement of operations related to final settlements of prior year cost reports and other settlements.

Notes to Consolidated Financial Statements
March 31, 2020
(Unaudited)

Generally, patients who are covered by third-party payors are responsible for related deductibles and coinsurance, which vary in amount. The Medical Center also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from standard charges. The Medical Center estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction prices including bad debts is determined by reducing the standard charge by any contractual adjustments, discounts and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue including bad debts in the period of the change. For the three months ended March 31, 2020 and 2019, revenue was increased by \$166,394 and \$487,236, respectively, due to changes in estimates of implicit price concessions for performance obligations satisfied in prior years.

Consistent with the Medical Center's mission, care is provided to patients regardless of their ability to pay. Therefore, the Medical Center has determined it has provided implicit price concessions to uninsured patients and patients with other uninsured balances (for example, copays and deductibles). The implicit price concessions included in estimating the transaction price represent the difference between amounts billed to patients and the amounts the Medical Center expects to collect based on its collection history with those patients.

The Medical Center disaggregates revenue from contracts with customers by type of service and payor source as this depicts the nature, amount, timing and uncertainty of its revenue and cash flows as affected by economic factors.

## 4. Healthcare Payment Proposals

The healthcare industry is subject to numerous laws and regulations of federal, state and local governments. Compliance with these laws and regulations is subject to future government review and interpretation as well as regulatory actions unknown or unasserted at this time.

Government activity continues to increase with respect to investigations and allegations concerning possible violations by healthcare providers of fraud and abuse statues and regulations, which could result in the imposition of significant fines and penalties as well as significant repayments for patient services previously billed. Management is not aware of any material incidents of noncompliance that have not been provided for in the accompanying financial statements; however, the possible future financial effects of this matter on the Medical Center, if any, are not presently determinable.

## 5. Subsequent Events

The Medical Center evaluated subsequent events for recognition or disclosure through May 14, 2020, the date the financial statements were available to be issued.

The COVID-19 pandemic continues to evolve rapidly in the State of New Jersey. In response to the pandemic, the Governor of New Jersey has declared a state of emergency and President Trump has declared a national state of emergency. Although the number of diagnosed, active cases in the tri-state area is just starting to show signs of leveling off in mid-May, the impact will continue to be felt for an extended period of time as providers begin to work toward bringing operations back once the declared state of emergencies are lifted.

The COVID-19 outbreak is disrupting business activity across a range of industries. The extent of the impact of COVID-19 on the Medical Center's operational and financial performance will depend on certain developments, including the duration and spread of the outbreak, impact on the demand for the Medical Center's services, the availability of staff and needed supplies, all of

Notes to Consolidated Financial Statements

March 31, 2020

(Unaudited)

which are uncertain and cannot be predicted. At this point, the extent to which COVID-19 will impact the Medical Center's future financial condition or results of operations is uncertain.

In April 2020, the Medical Center received from Medicare advance payments in the amount of \$25,998,463 for which payback is required within one year and CARES Act Stimulus payments in the amount totaling \$4,657,775 relating to the COVID-19 outbreak. The Medical Center also received three months advanced payments from Medicaid for Charity and GME subsidies in the amount of \$7,986,539. Further, the Medical Center received enhanced Medicare rates and State funds for the uninsured patients. In May 2020, the Medical Center received additional CARES Act Stimulus payments in the amount of \$27,620,560. The CARES Act Stimulus payments are subject to certain quarterly reporting requirements concerning how the funds are spent. Lastly, the Medical Center is evaluating and pursuing various grants and insurance recoveries including Business Interruption and Federal Emergency Management Agency (FEMA). The outcomes of these recoveries are not determinable at this time. In the consolidated statement of operations, \$333,011 has been recognized as net patient service revenue for the three months ended March 31, 2020.

## 6. New Accounting Pronouncements

Revenue Recognition

In 2018, the Medical Center adopted the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers (Topic 606) using the full retrospective approach. ASU No. 2014-09 supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance. The core principle under ASU No. 2014-09 is that revenues are recognized to depict the transfer of promised goods or services to customers (patients) in an amount that reflects the consideration at which the entity expects to be entitled in exchange for those goods or services. Additionally, ASU No. 2014-09 requires enhanced disclosures of revenue arrangements.

The most significant impact of adopting the new standard is within the consolidated statements of operations. Certain patient activity where collections was uncertain, previously included as net patient service revenue and separately recorded as the provision for bad debts, no longer meets the criteria for revenue recognition. Accordingly, net patient service revenue has been reduced by the amounts previously reported as the provision for bad debts and accordingly the provision for bad debts has been eliminated. Such patient activity, previously reported as the provision for bad debts (representing approximately \$4.2 million and \$4.3 million for the three months ended March 31, 2020 and 2019, respectively) is now classified as an implicit price concession. In addition, the Medical Center eliminated the related presentation of the allowance for doubtful accounts on the consolidated balance sheet as a result of the adoption of the new standard.

#### Financial Assets and Liabilities

In January 2016, the FASB issued ASU No. 2016-01, Recognition and Measurement of Financial Assets and Liabilities (Subtopic 825-10). The new guidance requires equity investments (except equity method investments or those that result in consolidation) to be measured at fair value with changes in fair value recognized in net income. Finally, ASU 2016-01 requires other specific investment presentation and disclosures in the consolidated financial statements for certain financial instruments. In 2018, the Medical Center adopted ASU No. 2016-01 on its consolidated financial statements. In addition, the Medical Center changed its accounting policy for its debt securities from available for sale to trading securities, whereby, equity and debt securities are combined in unrealized gains and losses in the consolidated statement of operations. As part of the adoption of ASU No. 2016-01 and the change in accounting policy, the Medical Center reported its changes in unrealized gains and (losses) on investments in the amounts of (\$13,116,591) and \$6,351,685 to be included in non-operating gains (losses) within revenues in excess of expenses for the three months ended March 31, 2020 and 2019, respectively.

Notes to Consolidated Financial Statements

March 31, 2020

(Unaudited)

#### Presentation of Financial Statements of Not-for-Profit Entities

In August 2016, the FASB issued ASU No. 2016-14, Not-for-Profit Entities (Topics 958): Presentation of Financial Statements of Not-for-Profit Entities and Liquidity and Availability of Resources. The new guidance is intended to improve and simplify the current net asset classification requirements and information presented in financial statements and notes that is useful in assessing a not-for-profit's liquidity, financial performance and cash flows. In 2018, the Medical Center adopted ASU No. 2016-14 on its consolidated financial statements. The Medical Center has adjusted the presentation of these consolidated financial statements accordingly. ASU No. 2016-14 has been applied retrospectively to all periods presented. The new standard changes the following aspects of the financial statements:

- The unrestricted net assets class has been renamed Net Assets Without Donor Restrictions;
- The temporarily and permanently restricted net asset classes have been combined into a single net asset class called Net Assets with Donor Restrictions;
- The financial statements include a disclosure about liquidity and availability of resources at March 31, 2020 and 2019 (Note 7).
- The functional expense disclosure for 2020 and 2019 includes expenses reported both by nature and function (Note 9).

## 7. Liquidity and Availability

As of March 31, 2020 and 2019, financial assets available for general expenditure within one year of the balance sheet date, consists of the following:

Financial assets available for general expenditures within one year of the balance sheet date, consists of the following:

	2020	2019
Cash and cash equivalents	\$ 116,732,191	\$ 125,414,919
Accounts receivable, net	29,556,872	27,421,813
Investments	29,556,872	31,350,001
Assets limited to use:		
Board-designated	106,470,452_	106,039,746
Total	*\$ 282,316,387	\$ 290,226,479

The Medical Center has certain board-designated assets limited to use which are available for general expenditure within one year in the normal course of operations. Accordingly, these assets have been included in the qualitative information above. The Medical Center has other assets limited to use for donor-restricted purposes, debt service, and for other internally designated funds.

As part of the Medical Center's liquidity management plan, cash in excess of daily requirements are invested in short-term investments and money market funds. The board of trustees established a funded depreciation account for future capital needs of the Medical Center; these funds may be drawn upon, if necessary, to meet unexpected liquidity needs.

Additionally, the Medical Center maintains a \$5 million line of credit that expires December 10, 2020, As of March 31, 2020, \$5 million remained available on the Medical Center's line of credit.

Notes to Consolidated Financial Statements March 31, 2020 (Unaudited)

#### 8. Right-of-Use Operating Leases

In February 2016, the FASB issued Accounting Standards Update ASU No. 2016-02, Leases (Topic 842). ASU No. 2016-02 was issued to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Under the provisions of ASU No. 2016-02, a lessee is required to recognize a right-to-use asset and lease liability, initially measured at the present value of the lease payments, in the balance sheet. In addition, lessees are required to provide qualitative and quantitative disclosures that enable users to understand more about the nature of the Medical Center's leasing activities. The Medical Center has retrospectively adopted the guidance in ASU No. 2016-02 for years beginning after December 15, 2018. The Medical Center has determined that as a result of ASU No. 2016-02, on January 1, 2019, the Medical Center has recorded right-of-use assets and lease liabilities of approximately \$14.4 million on the consolidated balance sheet.

The Medical Center has operating leases for equipment leases which are for medical equipment to provide medical services and for real estate leases which are for administrative office space and space to provide outpatient medical services. For the equipment leases, the equipment will be returned to the lessor at the end of the respective leases. The leases have remaining lease terms of 1 year to 10 years, some of which include options to extend the leases for up to 5 years.

For the three months ended March 31, 2020, the components of the leases were as follows:

To the the character of, 2026,		Equipment Leases	R	eal Estate Leases		Total
Operating lease expense	\$	427,619	\$	510,455	\$	938,074
For the three months ended March 31, 2020, s as follows:		mental cash flo Equipment Leases		ormation relate leal Estate Leases	ed to	leases was
Cash paid for amounts included in the measure		of lease liabili				
Operating cash flows from operating leases	\$	433,595	\$	504,554	\$	938,149
As of March 31, 2020, supplemental balance s	heet i	nformation rela	ated to	o leases was a	s foll	ows:
	E	Equipment	F	teal Estate		
		Leases		Leases		Total
Operating Leases			_			
Right-of-use assets		4,934,540	\$	6,440,684	\$	11,375,224
Lease liabilities	\$	4,934,540	\$	6,440,684	\$	11,375,224
Weighted Average Remaining Lease Term Operating leases		5 years		7 years		5.8 years
Weighted Average Discount Rate Operating leases		6%		6%		6%

Notes to Consolidated Financial Statements

March 31, 2020

(Unaudited)

As of March 31, 2020, maturities of lease liabilities were as follows:

	Equipment		Real Estate			
	Leases			Leases		Total
Year Ending December 31,						
2020 (nine months)	\$	1,300,785	\$	1,513,661	\$	2,814,446
2021		1,313,374		1,302,071		2,615,445
2022		1,280,245		1,077,524		2,357,769
2023		1,157,690		1,092,173		2,249,863
2024		1,067,467		1,107,260		2,174,727
Thereafter		131,077		2,395,241		2,526,318
Total lease payments		6,250,638		8,487,930	*	14,738,568
Less imputed interest		(1,316,098)		(2,047,246)		(3,363,344)
Total	\$	4,934,540	\$	6,440,684	\$	11,375,224

#### 9. Functional Expenses

The financial statements report certain categories of expenses that are attributable to one or more program or supporting functions of the Medical Center. These expenses include depreciation, interest and amortization, administration, communications, media production, information technology, and facilities operations and maintenance. Depreciation is allocated based on square footage and interest is allocated based on usage of space. Costs of other categories were allocated on estimates of time and effort.

Functional expenses for the three months ended March 31, 2020

		Healthcare Services	 dical Office Building	Seneral and diministrative	 Total
Salaries and wages	\$	30,874,583	\$ _	\$ 4,587,057	\$ 35,461,640
Employee benefits		6,537,804	-	971,326	7,509,130
Supplies and other		22,752,143	223,425	6,208,744	29,184,312
Depreciation		2,356,236	95,009	317,010	2,768,255
Interest and amoritization		574,060	-	 77,601	 651,661
Total	\$	63,094,827	\$ 318,434	\$ 12,161,737	\$ 75,574,998_

Functional expenses for the three months ended March 31, 2019

	Healthcare Services	Me	edical Office Building	Seneral and dministrative	Total
Salaries and wages	\$ 30,098,342	\$	-	\$ 4,471,730	\$ 34,570,072
Employee benefits	6,318,270		-	938,709	7,256,979
Supplies and other	22,286,775		208,093	6,078,844	28,573,712
Depreciation	2,400,272		99,020	323,224	2,822,516
Interest and amoritization	589,038		-	 79,625	668,663
Total	\$ 61,692,697	\$	307,113	\$ 11,892,132	\$ 73,891,942

Notes to Consolidated Financial Statements March 31, 2020 (Unaudited)

#### 10. Charity Care and Subsidy Revenue

The Medical Center receives subsidy payments from the State of New Jersey to partially fund charity care and certain other program costs. Subsidy payments included in other revenue for the three months ended March 31, 2020 and 2019 are as follows:

	2020			2019		
Charity care	\$	7,112,806	\$	7,558,981		
Delivery System Reform Incentive Payment (DSRIP)		2,153,180		1,212,917		
Mental health		452,878		452,878		
Total	_\$_	9,718,864	_\$_	9,224,776		

The Medical Center is amortizing the DSRIP incentive payments over the program's respective fiscal years, which end on June 30. For the three months ended March 31, 2020 and 2019, \$2,153,180 and \$1,212,917 of the incentive payments were recognized in other revenue in the consolidated statement of operations, respectively.

The Medical Center, as part of its mission, provides medical care without charge or at reduced charges to residents of its community through the provision of charity care. The Medical Center's definition of charity care is in accordance with state regulations and includes services provided at no or partial charge to the uninsured or underinsured.

Patients who meet the State of New Jersey's criteria for charity care are provided care without charge or at amounts less than established rates. Such amounts determined to qualify as charity care are not reported as revenue. Charges for charity care rendered were \$33,241,767 and \$36,370,755 for the three months ended March 31, 2020 and 2019, respectively.

#### 11. Long-term Debt

The Medical Center has outstanding New Jersey Health Care Facilities Financing Authority (the "Authority") tax exempt Refunding and Revenue Bonds, Series 2016A (the "Series 2016A Bonds"), bearing interest at 5 percent per annum. The initial \$13,810,000 in proceeds from the sale of the Series 2016A Bonds were used to refund Series 2006 Bonds and pay for debt issuance costs. The principal amounts are payable annually on July 1, and interest is payable semiannually on January 1 and July 1 through 2030. The Series 2016A Bonds are collateralized by substantially all of the Obligated Group's property and equipment and gross receipts.

The Medical Center has outstanding Authority Refunding Bonds, Series 2017A (the "Series 2017A Bonds"), bearing interest at 5 percent per annum. The initial \$82,970,000 in proceeds from the sale of the Series 2017A Bonds combined with the debt service reserve funds released by the trustee relating to the Series 2007A Bonds and Series 2007B Bonds were used to refund Series 2007A Bonds and Series 2007B Bonds and pay debt issuance costs. The principal amounts are payable annually on July 1, and interest is payable semiannually on January 1 and July 1 through 2030. The Series 2017A Bonds are collateralized by substantially all of the Obligated Group's property and equipment and gross receipts.

Notes to Consolidated Financial Statements March 31, 2020 (Unaudited)

#### 12. Cogeneration Energy Project

The Medical Center has received approval from the Energy Resilience Bank ("ERB"), for a plant electrical and steam generation project. The project provides additional energy production which will be powered by natural gas during prolonged electrical outages. The project has an estimated cost of \$10.1 million. The financing of the project consists of a combination of grants for \$6.6 million and a loan from the Department of Housing and Urban Development ("HUD") for approximately \$3.5 million at 2% payable over 20 years. A portion of the grants, approximately \$520,000, has to be repaid over ten years, interest free. Final construction and engineering costs were finalized and approved by ERB and HUD and the transaction closed during the first quarter of 2019 and construction is expected to begin in the first quarter of 2020. The debt and grants will be drawn down as construction occurs and there is no interest charged during the construction period. At the completion of the project, the loan will be finalized and payment amortization will begin. At March 31, 2020 and 2019, project costs of \$501,748 and \$386,376, respectively, are reflected in property and equipment, net and in deferred grant revenue on the consolidated balance sheet.

#### 13. Administrative Services Building Project

In June of 2019, the Medical Center signed various agreements with a developer subject to various regulatory approvals and the developer being able to obtain financing. The project includes the demolishment of the existing Administration Services Building and construction of an approximately 46,000 rentable square feet (RSF) Medical Office building, to be owned by the developer or designee. Further the Medical Center entered into agreements with the developer for a ground lease, medical office space lease and the construction of a parking garage. The ground lease covers a term of 50 years, .6455 of an acre and annual rental income of \$47,004, indexed by annual increases of 2.5% for the first ten years then adjusted to market value. The medical office space lease key terms are for a term of 15 years, for approximately 18,000 RSF, at \$25.35 RSF indexed by annual increases of 2.5% plus operating expenses and fit out costs of approximately \$4.3 million. Lastly, the key terms of the parking garage construction contract are for a four story, 300 spaces garage for \$10,188,472. At the commencement date, (completion of construction) a final determination will be made to determine the accounting for the leases. The expected completion date is 12 to 18 months from the date of obtaining all necessary approvals. All necessary approvals have not presently been obtained.

#### 14. Discussions With RWJ Barnabas

The Medical Center is currently engaged in potential affiliation negotiations with RWJ Barnabas Health, Inc. (the "Corporation") located in West Orange, New Jersey. The Medical Center and the Corporation have entered into a Non-disclosure Agreement and a Letter of Intent. It is not currently possible to determine if, or when, a transaction with the Corporation will be completed.

# TRINITAS REGIONAL MEDICAL CENTER MARCH 31, 2020 AND 2019 INPATIENT STATISTICS

	2020	2019
	ACTUAL	ACTUAL
	TOTAL	TOTAL
ADMISSIONS	1	
MEDICAL	1,189	1,557
SURGICAL	267	392
OBSTETRICS	305	336
	292	309
NEWBORN		374
ADULT & ED PSYCH	377	
ADOLESCENT PSYCH	96	141
DEVELOP DISABLED	63_	66
	2,589	3,175
SAME DAY SURGERY	855	967
	3,444	4,142
INTERDATEDIA TE DOVOII	40	48
INTERMEDIATE PSYCH		40
RESIDENTIAL UNIT	3	
LONG TERM CARE	48	53
	91	103
PATIENT DAYS	1	
MEDICAL		8,581
SURGICAL	2,895	3,133
	2,893 824	901
OBSTETRICS	805	
NEWBORN	0.0.4	914
ADULT & ED PSYCH	3,924	3,726
ADOLESCENT PSYCH	1,107	1,144
DEVELOP DISABLED	795	783
	17,381	19,182
SAME DAY SURGERY	855	967
	18,236	20,149
INTERMEDIATE PSYCH	1,477	1,759
RESIDENTIAL UNIT	1,365	1,350
LONG TERM CARE	10,649	10,430
LONG TERM CARE	13,491	13,539
ALOS	]	
MEDICAL	5.9	5.5
SURGICAL	10.8	8.0
OBSTETRICS	2.7	2.7
NEWBORN	2,8	3.0
ADULT & ED PSYCH	10.4	10.0
ADOLESCENT PSYCH	11.5	8.1
DEVELOP DISABLED	12.6	11.9
TOTAL W/O SDS	6.7	6.0
	26.5	36.5
INTERMEDIATE PSYCH	36.9	36.6
RESIDENTIAL UNIT	455.0	675.0
LONG TERM CARE	221.9	196.8
	148.3	131.4
CARDIAC CATH LAB I/P	7	
CARDIAC CATHS		99
EMERGENCY ANGIO	7	8
ELECTIVE ANGIO	23	23
OTHER	37	42
	126	172
TOTAL	120	1/4

# TRINITAS REGIONAL MEDICAL CENTER MARCH 31, 2020 AND 2019 OUTPATIENT STATISTICS

	ACTUAL	2019 ACTUAL
	YTD	YTD
EMERGENCY ROOM	L	
NEWPOINT-PSYCH O/P VISITS	370	486
WILLIAMSON O/P VISITS	13,051	13,295
TOTAL O/P	13,421	13,781
NEWPOINT ADMISSIONS	377	378
WILLIAMSON ADMISSIONS	1,315	1,733
TOTAL ADMISSIONS	1,692	2,111
% Total ADMISSIONS FROM ER	65,35%	66.49%
TOTAL EMERGENCY ROOM VISITS	15,113	15,892
OBSERVATION		
WSC OBSERVATON CASES	934	769
NPC OBSERVATON CASES	23	24
TOTAL OBSERVATION	957	793
CLINICS		
ADULT OP SERVICES	15 97.6	19,344
PC (PARTIAL HOSP) SERVICES	15,874 1,542	1,850
CHILD/ADOL OP SERVICES	7,453	8,105
YIP (AFTER SCHOOL)	1,397	1,870
IOP SERVICES	520	644
OTHER CHILD/ADOL SERVICES	14,654	16,987
BAYONNE MH CLINIC	5,606	6,519
TOTAL PSYCH CLINICS	47,046	55,319
D D MDDGM GI DAG	* 003	2.004
D.B.HERSH CLINIC PEDIATRIC HEALTH CENTER	1,803	2,001
WOMENS HEALTH CENTER	1,492 4,344	1,045 4,568
WOUND HEALING CENTER	998	940
MEDICAL CLINIC (EID)	321	385
TOTAL MEDICAL CLINICS	8,958	8,939
TOTAL CLINICS	56,004	64,258
CANCER CENTER		
OFFICE VISITS	1,702	1,714
INFUSION TREATMENTS	1,573	1,606
RADIATION TREATMENTS	918	1,213
CANCER CENTER TOTAL	4,193	4,533
	4,193	4,333
PRIVATE AMBULATORY	216	450
SLEEP CENTER	316	359
OTHER PRIVATE REFFERRED (1) TOTAL PRIVATE AMBULATORY	11,684 12,000	13,186 13,545
A D A SAD A AND TAX BY CRUMP USING BUILT BUTCH	12,000	10,000
O/P RENAL TREATMENTS		
O/P HEMODIALYSIS	5,199	5,084
	589	365
O/P HEMODIALYSIS HOME DIALYSIS CRANFORD RENAL	589 592	365 0
O/P HEMODIALYSIS HOME DIALYSIS CRANFORD RENAL LINDEN SATELLITE	589 592 3,146	365 0 3,173
O/P HEMODIALYSIS HOME DIALYSIS CRANFORD RENAL LINDEN SATELLITE TOTAL RENAL TREATMENTS	589 592	365 0
O/P HEMODIALYSIS HOME DIALYSIS CRANFORD RENAL LINDEN SATELLITE TOTAL RENAL TREATMENTS AMBULANCE RUNS	589 592 3,146	365 0 3,173 8,622
O/P HEMODIALYSIS HOME DIALYSIS CRANFORD RENAL LINDEN SATELLITE TOTAL RENAL TREATMENTS AMBULANCE RUNS SCTU RUNS	589 592 3,146 9,526 1,266 62	365 0 3,173 8,622 1,526 60
O/P HEMODIALYSIS HOME DIALYSIS CRANFORD RENAL LINDEN SATELLITE TOTAL RENAL TREATMENTS AMBULANCE RUNS	589 592 3,146 9,526	365 0 3,173 8,622
O/P HEMODIALYSIS HOME DIALYSIS CRANFORD RENAL LINDEN SATELLITE TOTAL RENAL TREATMENTS AMBULANCE RUNS SCTU RUNS	589 592 3,146 9,526 1,266 62	365 0 3,173 8,622 1,526 60
OP HEMODIALYSIS HOME DIALYSIS CRANFORD RENAL LINDEN SATELLITE TOTAL RENAL TREATMENTS AMBULANCE RUNS SCTU RUNS MICU RUNS	589 592 3,146 9,526 1,266 62 753	365 0 3,173 8,622 1,526 60 893
O/P HEMODIALYSIS HOME DIALYSIS CRANFORD RENAL LINDEN SATELLITE TOTAL RENAL TREATMENTS AMBULANCE RUNS SCTU RUNS MICU RUNS SDS (FROM IP SCHEDULE) TOTAL O/P VISITS (INCLUDING SDS)	589 592 3,146 9,526 1,266 62 753 855	365 0 3,173 8,622 1,526 60 893
O/P HEMODIALYSIS HOME DIALYSIS CRANFORD RENAL LINDEN SATELLITE TOTAL RENAL TREATMENTS AMBULANCE RUNS SCTU RUNS MICU RUNS SDS (FROM IP SCHEDULE) TOTAL O/P VISITS (INCLUDING SDS) PAID PHYSICIAN ENCOUNTERS	589 592 3,146 9,526 1,266 62 753 855	365 0 3,173 8,622 1,526 60 893
O/P HEMODIALYSIS HOME DIALYSIS CRANFORD RENAL LINDEN SATELLITE TOTAL RENAL TREATMENTS AMBULANCE RUNS SCTU RUNS MICU RUNS SDS (FROM IP SCHEDULE) TOTAL O/P VISITS (INCLUDING SDS) PAID PHYSICIAN ENCOUNTERS  CARDIAC CATH LAB O/P CARDIAC CATHS	589 592 3,146 9,526 1,266 62 753 855 99,037 40,633	365 0 3,173 8,622 1,526 60 893 967 108,978
O/P HEMODIALYSIS HOME DIALYSIS CRANFORD RENAL LINDEN SATELLITE TOTAL RENAL TREATMENTS  AMBULANCE RUNS SCTU RUNS MICU RUNS SDS (FROM IP SCHEDULE)  TOTAL O/P VISITS (INCLUDING SDS)  PAID PHYSICIAN ENCOUNTERS  CARDIAC CATH LAB O/P CARDIAC CATHS ELECTIVE ANGIOPLASTY	589 592 3,146 9,526 1,266 62 753 855 99,037 40,633	365 0 3,173 8,622 1,526 60 893 967 108,978
O/P HEMODIALYSIS HOME DIALYSIS CRANFORD RENAL LINDEN SATELLITE TOTAL RENAL TREATMENTS AMBULANCE RUNS SCTU RUNS MICU RUNS SDS (FROM IP SCHEDULE) TOTAL O/P VISITS (INCLUDING SDS) PAID PHYSICIAN ENCOUNTERS  CARDIAC CATH LAB O/P CARDIAC CATHS	589 592 3,146 9,526 1,266 62 753 855 99,037 40,633	365 0 3,173 8,622 1,526 60 893 967 108,978

# Debt Service Calculation Certificate (Twelve Month Rolling Average) (Unaudited)

	-	March 2020
Funds Available for Debt Service		
Net increase in unrestricted net assets	\$	(374,766)
Reconciling items:		
Depreciation		10,730,935
Interest and amortization		2,621,356
Net assets released from restrictions used for		
purchase of property and equipment		(1,975,043)
Change in net unrealized gains and losses on investments		5,159,153
Total	\$	16,161,635
Maximum annual debt service	\$	9,617,217
Actual ratio		1.68
Required ratio		1.25

# Cushion Ratio Calculation Certificate (Twelve Month Rolling Average) (Unaudited)

	March 2020	
Cushion Ratio Cash and investments	\$	154,889,087
Internally designated funds  Total	\$	111,056,417 265,945,504
Maximum annual debt service Series 2016A and 2017A bonds payable Loan payable	\$	9,549,000 68,217
Total maximum annual debt service	\$	9,617,217
Cushion ratio  Required ratio		27.65 1.25
roquirou rado		1120